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Background: This thesis is about pre-eclampsia in Tanzania and Norway, and the differences 
and similarities in how they follow up pre-eclamptic patients, the management and 
treatment, and the outcome for the mother and the foetus/neonate. It is a combined 
literature and case study.  
Material and methods: I followed up a total of 6 patients at the University Hospital of 
Northern Norway in Tromsø and 2 patients at Haydom Lutheran Hospital in Tanzania. At 
Haydom Lutheran Hospital I collected information about their local guidelines. In Norway I 
searched for the national guidelines in literature. I also collected information from a birth 
protocol at the University Hospital of Northern Norway, Tromsø. I searched and read 
through a lot of articles, and chose the ones that highlighted the title of the thesis. 
Results: Comparison between the two countries shows that the incidence of pre-eclampsia is 
probably higher in developing countries. Most of them who develop pre-eclampsia are 
primigravidae. Caesarean section is performed in 70% of women with pre-eclampsia or 
complications due to pre-eclampsia. There exist several medications used for treatment of 
this disease. The standard of New-born Intensive in these two institutions was very different, 
and the new-born neonate was in greater risk in Tanzania compared to Norway. Since pre-
eclampsia may lead to prematurity, they are in greater risk in Tanzania due to lack of 
equipment. A big problem in Tanzania is that as many as 50% deliver their baby at home, 
which is a huge risk factor for both the mother and the foetus. 
Conclusion: The guidelines for these two institutions were somewhat the same, but it is 
more difficult to follow-up patients in Tanzania due to more challenges in great travel 
distance, expensive costs of care and lower socioeconomic standard. They used somewhat 
the same medications in Norway and Tanzania. I found some small differences in which drug 
they preferred to use. Because of lower socioeconomic standard in Tanzania, both the 
mother and the foetus have a worse outcome compared to Norway, and that can also be 
due to home deliveries. If the pre-eclamptic woman is able to come to Haydom Lutheran 





2.0.1 What is pre-eclampsia? A definition 
Pre-eclampsia is diagnosed if a pregnant woman has hypertension and proteinuria after 20 
weeks of pregnancy [1]. Pre-eclampsia is a multiorgan disease by an unknown aetiology [2]. 
It can be asymptomatic until the disease become more severe, with debut of cerebral 
symptoms like generalized seizures (eclampsia) or cortical blindness [3]. About 10 % of pre-
eclampsia occurs before 34 weeks of gestation, and this is why delivery due to pre-eclampsia 
is one of the reasons for preterm births. Delivery is the only cure, and decisions regarding 
when to deliver and mode of delivery should be based on a combination of maternal and 
foetal factor [2]. In such case pre-eclampsia represents a major health problem and affects 
both maternal and foetal health. Pre-eclampsia may cause intrauterine growth retardation, 
preterm birth, perinatal death, antepartum and postpartum haemorrhage, acute hepatic 
and renal failure and maternal death [4]. 
Hypertensive disorders, including pre-eclampsia, are important factors of severe morbidity, 
disability and death among mothers, foetus and infants. Management of pre-eclampsia aims 
to minimalize any pregnancy related complications, avoiding unnecessary prematurity and 
maximize maternal and perinatal/neonatal survival. Pre-eclampsia and eclampsia are the 
major causes of maternal and perinatal morbidity and mortality. Most of the deaths are 
avoidable, and optimizing health care to both prevent and treat these women are important 
steps towards achieving the Millennium Development Goals [5]. 
2.1 Presentation of the two study sites 
This study is done at Haydom Lutheran Hospital in Tanzania and at the University Hospital of 
Northern Norway, Tromsø, where I followed up a total of 8 patients with pre-eclampsia 
and/or severe complications due to pre-eclampsia.  
Haydom Lutheran Hospital became the chosen hospital in Tanzania because I had friends 
living there and they gave me contact with this hospital. It is a district hospital 300 km from 
Arusha, and is situated in a rural site in the Mbulu area in northern Tanzania. The hospital 
have 450 beds and serves approximately 450 000 people in the area. People living there are 
very poor, the roads are extremely bad and public transport is almost non-existing. Primary 
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care does not exist, except mother-baby-stations organized by the hospital. At the birth 
department there are approximately 3 500 births a year. The average parity of each woman 
is 5,24. 50 % of the mothers deliver at home. Some of them do not go to the hospital 
because it is expensive to get there and to be admitted [6].  
The University Hospital of Northern Norway, Tromsø, became the chosen hospital in Norway 
because it is my university hospital. This hospital serves the population in the northern part 
of Norway.  It is a big region hospital, but also a local hospital for the county of Troms and 
parts of Nordland [7]. In the period from 20.08.12 – 20.08.13 there were 1342 deliveries at 
the birth department (see table 9). 
2.2 Objectives 
My objectives were to identify risk factors of pre-eclamptic women and to point out the 
limitations and challenges with these kinds of patients at Haydom Lutheran Hospital in 
Tanzania and at The University Hospital of Northern Norway in Tromsø. There were four 
specific points I wanted to look at: The follow-up of pre-eclamptic patients, the management 
and treatment, the pregnancy outcome for the foetus/neonate and the pregnancy outcome 
for the mother.  
2.2.1 The follow-up of pre-eclamptic patients 
Pregnancy care in Norway: The pregnant women either go to a mid-wife or a doctor. The 
first control is in week 8-12 where they receive information regarding recommended weeks 
of control, way of living while pregnant, checks weight and BMI, ask for smoking, course with 
emphasis on becoming parents and information regarding different tests and examination. 
They measure blood pressure (BP), haemoglobin (Hb), blood typing, rhesus-status, 
antibodies, immunity of rubella, HIV, syphilis, hepatitis B and C on indication, screening for 
asymptomatic bacteriuria in women who has had repeated urine tract infections (UTI’s), 
checks for protein- and glucoseuria and do a chlamydia test in women below 25 years old or 
on indication. The first ultrasound is in week 17-19 of gestation to consider the exact week 




In week 24, 28, 32, 36, 38, 40 and 41 they do symphysis- fundus measurement, checks BP, 
weight, protein- and glucoseuria and auscultation of the foetal heart. In week 28 and 36 it is 
also control of antibodies in Rhesus negative women. Lie of the baby is checked in week 36, 
38, 40 and 41. With breach presentation in week 36, the woman should be referred to an 
ultrasound for consideration of external inversion. In week 41 she is referred to assessment 
due to overtime [8].  
Pregnancy care in Tanzania: There are 27 mother-baby-stations driven by Haydom Lutheran 
Hospital in Tanzania. 6 of the stations are so far away that the employees have to go there 
by a small plane. In one year nearly 30 000 mothers and 70 000 children are examined at 
these stations. The pregnant woman is sent to control in week 16, 20-24, 28-32 and 36 of 
gestation and the management at this site involves: 
- History and information regarding previous pregnancies and births 
- Physical examination, including palpation and examination of the foetus 
- Health information, education and supervising 
- Lab tests: haemoglobin, blood type, syphilis and vaccine against tetanus 
- Malaria prophylaxis twice during pregnancy [6]. 
Developing countries have more challenges regarding poverty, long distance to the hospital 
and lack of doctors. I wanted to see and compare to Norway how this affects how they are 
able to follow-up pre-eclamptic patients in Tanzania, and the outcome regarding this. 
2.2.2 The management and treatment 
There are many ways of treating pre-eclamptic women. Should the mother be at home or 
admitted to the hospital? This depends on whether her condition is stable or not. In Norway 
it is recommended that all pregnant women with diastolic pressure > 90 mm Hg and newly 
discovered proteinuria should be admitted because it is a condition that can develop to 
become severe quite rapid. If the condition is stable, she can go home with information 
about severe symptoms and frequent monitoring. Pregnant women with severe pre-
eclampsia, eclampsia and mild pre-eclampsia that occur in week 24-35 of gestation should 
stay at the hospital until they have delivered [9].  
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With pre-eclampsia before week 27 of gestation, the goal is to prolong the pregnancy which 
provides the best outcome for the foetus. The risk for the mother and the foetus should be 
monitored frequently. In Norway the monitoring of the mother consist of considering her 
general condition (where we emphasize headache, visual disturbances, pain in the 
abdomen), blood pressure, if she gains weight, urine and the degree of potential oedema.  
Monitoring of the foetus consists of doing a non-stress test, which is done after week 32 of 
gestation, to check the baby’s well-being. This will be done with an ultrasound to control the 
activity of the foetus, to check and measure volume of amniotic fluid, foetal growth and 
maturity of the placenta. Measurement of the blood flow in a. umbilicalis and a. cerebri 
media are done some places. Increased resistance in a. umbilicalis can be an expression for 
pathologic conditions in the placenta. The only curative treatment of pre-eclampsia is 
delivery. They aim to give vaginal birth, but in some situations caesarean section is required 
[9].  
There are a number of different medications that can be used treating pre-eclampsia, where 
Methyldopa (Aldomet), Labetalol (Trandate), Calcium antagonist and Beta blockers are 
appropriate medications [9]. It is expected that there are greater challenges treating patients 
with pre-eclampsia in developing countries, because it is more common with a delay in 
seeking help, delay to get in time to the hospital, and delay in health care [10]. I wanted to 
see if these expectations were correct and if they had the same management and used 
somewhat the same drugs in Tanzania as in Norway. I wanted to learn if the challenges 
developmental countries have could make this more difficult. 
2.2.3 The pregnancy outcome for the foetus/neonate 
Perinatal mortality is death of a foetus or death during first week of life, which also is early 
neonatal death, with birth weight of 500 grams or more [11]. The progress on United 
Nation’s Millennium Developmental goal 4 (MDG4) to reduce the mortality of children under 
five years old has been slower than anticipated. The main reason for that is due to high 
neonatal mortality in developing countries. Worldwide there are about 4 million neonatal 
deaths each year, and three quarter of these occur in the first week of life, having a huge risk 
at the first day of life [12]. I wanted to look at if pre-eclampsia could be one of the reasons 
why there still are a large number of neonatal deaths in developing countries such as 
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Tanzania. Pre-eclampsia is also the reason for approximately 20 % of all preterm births [13]. 
With that acknowledge, I wanted to see if prematurity caused by pre-eclampsia could be a 
reason for neonatal death.  
2.2.4 The pregnancy outcome for the mother 
Definition of maternal death from The World Health Organization and ICD-10 is the death of 
a woman while she is pregnant or within 42 days after delivery. The eight millennium 
development goal is to reduce maternal mortality rate by 75 % from 1990 to 2015. The MMR 
(maternal mortality rate) in developing countries is quite high with 450 maternal deaths per 
100 000 live births. In developed countries in comparison it is 9 per 100 000 live births [2]. I 
wanted to look at why there are such a high number of maternal deaths in developing 
countries such as Tanzania compared to Norway which is a developed country with fewer 
maternal deaths. I wanted to learn if pre-eclampsia could be a reason for that.  
2.3 Theory 
2.3.1 Epidemiology 
WHO estimate the incidence of pre-eclampsia to be seven times higher in developing 
countries compared to industrial countries. In Tanzania the incidence varies from 1.8% to 
7.1% [10]. In my own research, searching through the birth protocol from 20.08.12-20.08.13 
at the University Hospital of Northern Norway, Tromsø, I found the incidence to be 2.8 % 
(see table 9). 65 – 75 % of pre-eclamptic women are primigravidae [9].  
2.3.2 Pathophysiology 
The aetiology of pre-eclampsia is not fully understood, but it is known that the 
pathophysiology of this disease involves maternal and foetal/placental factors. It is 
necessary to have placental tissue to develop pre-eclampsia [2]. Disturbed interactions 
between foetal trophoblasts and maternal cells can cause defective trophoblast invasion, 
and this is considered to be important in the pathophysiology [13]. The cytotrophoblast cells 
infiltrate the spiral arteries in the decidual portion, but fail to go through the myometrial 
segment [2]. Reduced placental perfusion and spiral artery remodelling are also considered 
to create oxidative stress and a release of inflammatory factors into the maternal circulation 
[13]. Spiral arteries fail to develop into large vascular channels, and a shallow placentation 
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leads to dysfunctional placenta. This combined with atherosis may be one of the causes for 
reduced placental perfusion, and poor placental perfusion is proposed to be the cause of 
pre-eclampsia.  Reduced placental perfusion results into different production of agents in 
the placenta, and this leads to activated and injured endothelial cells. Trophoblast products 
cause this disease through endothelial dysfunction and cell damage through deported 
microvilli. Endothelial dysfunction increases sensitivity to normal endogenous pressors. The 
results of that are increased vascular permeability and activation of the coagulation cascade. 
There are two main factors that we know of that could be causes of pre-eclampsia: poor 
placental perfusion and endothelial dysfunction [2].  
 
  
Figure 1: Pathogenesis of pre-eclampsia [14]. 
2.3.3 Predisposing factors: 
- Pre-eclampsia in a previous pregnancy 
- First pregnancy (null parity, primigravidae) 
- 10 years since a previous pregnancy 
- Age 40 or more (older maternal age) 
- BMI > 35 (obesity) 
- Multiple pregnancy 
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- Family history of pre-eclampsia 
- Underlying medical conditions that were present before the pregnancy, such as 
hypertension, renal disease, diabetes and anti-phospholipid antibodies [15].  
2.3.4 Diagnostics 
To obtain correct diagnose of the pregnant woman with a high blood pressure, one have to 
distinguish between several groups:  
 Chronic hypertension  
 Pregnancy induced hypertension 
 Mild pre-eclampsia 
 Severe pre-eclampsia [9].  
Chronic hypertension: Hypertension that is proven before week 20 of gestation [9]. 
Pregnancy induced hypertension: If a former normotensive woman got a systolic blood 
pressure > 140 mm Hg and/or diastolic blood pressure > 90 mm Hg, and she does not have 
proteinuria, it is called pregnancy induced hypertension [9].  
Mild pre-eclampsia: Mild pre-eclampsia is classified as a syndrome with hypertension 
(>140/>90 mm Hg), proteinuria (>0, 3 g/24 h) and possible edema [9].  
Severe pre-eclampsia: Severe pre-eclampsia occurs if the systolic blood pressure is > 160 mm 
Hg and/or the diastolic blood pressure is > 110 mm Hg, or if the loss of protein is > 3 g per 
day or more. Further, if the loss of protein is above 3 g/day, it is also severe pre-eclampsia, 
even though the blood pressure only satisfies the requirement of mild pre-eclampsia [9].  
2.3.5 Complications 
Eclampsia: Both mild and severe pre-eclampsia occurs after 20 weeks of gestation, and can 
lead to severe complications such as eclampsia if not treated [10]. Symptoms can be 
headache, visual disturbances and restlessness [16]. The occurrence is convulsions 
superimposed on pre-eclampsia, during pregnancy, delivery or in the first 10 days after 
delivery, that cannot be attributed to any other cases [2]. As with pre-eclampsia the entire 
aetiology of eclampsia is not understood either. 5- 8 % of women with pre-eclampsia 
present with eclampsia in developing countries [5]. Eclampsia is associated with 10 % of 
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maternal deaths and 2-3 % of those who are affected get permanent neurological sequel 
[16], [17].  
Abruptio placentae: About 1 % of all pregnancies is complicated by abruptio placentae, and 
can be a complication to severe pre-eclampsia. Abruptio placentae can occur dramatically 
with pain, bleeding and affected general condition, but symptoms are not always present. It 
can be life threatening both for the mother and the foetus if the abruption is total [16]. 
HELLP-syndrome: In the term HELLP the H stands for haemolysis, E and L for elevated lever 
enzymes (abnormal liver function tests), L and P for low platelets (thrombocytopenia). This 
condition is rare, but occurs more frequently than eclampsia. Symptoms of HELLP are 
epigastric pain or pain below right costae, and sometimes nausea and vomiting are present 
[16]. This condition is associated with endothelial damage and is an important predictor for 
organ dysfunction and mortality [5]. 
2.3.6 Medications 
Mechanism of action of the different medications used in Tanzania and Norway: 
Methyldopa (Aldomet): Methyldopa is taken into neurones by an active transport and is 
converted to alpha methyl noradrenaline which is a potential alpha-2-reseptorstimulator. 
Thereby the blood pressure decreases by inhibition of sympathetic nerve system primarily 
by CNS-effects, but also by an effect on the peripheral sympathetic nerve endings [18]. 
Labetalol (Trandate): Labetalol is an adrenergic alpha-1-betareceptorantagonist which 
lowers the blood pressure by several mechanisms. Alpha-1-receptor blockade is more 
prominent in Labetalol than other adrenergic alpha-1-betareceptorantagonist medications. 
It reduces peripheral resistance. Beta-receptor blockade lowers the heart rate and prevents 
tachycardia [18]. 
Nifedipine (Adalat): Nifedipine is a calcium-antagonist which inhibits influx of calcium ions 
through slow calcium channels primarily in smooth muscle cells in vessel wall, but also in 
myocardial cells. The effects are vasodilatation and reduced myocardial contraction and 
heart rate. In normal dose of Nifedipine the conduction velocity in the AV node will not be 
affected, as it will in other calcium-antagonists. It might give initial tachycardia, but to 
reduce that one can give prolonged-release tablets which gives slow absorption [18]. 
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Hydralazine: Hydralazine causes selective dilatation in the arteriole without affecting known 
receptors. It seems likely to be converted to NO and thereby increase cGMP in smooth 
muscle and perhaps open potassium channels. Hydralazine should never be used alone, and 
in patients with pre-eclampsia it is often used together with Methyldopa (Aldomet) [18]. 
Magnesium sulphate: Magnesium sulphate is given if an eclamptic woman gets generalized 
tonic-clonic seizures inside hospital [18]. It can be used for prevention and treatment of 
eclampsia [5], [17], [19]. 
Calcium gluconate: That can be administrated if there is suspected magnesium toxicity after 
administration of magnesium sulphate. It will reverse the effects of the toxicity [19]. 
Diazepam: Diazepam is a part of the group benzodiazepines. It has an effect on specific 
receptors and alters the inhibitory effect of GABA in the central nervous system [18]. 
Misoprostol (Cytotec): Misoprostol is a prostaglandin which will make the uterus contract, 
and is used in induction of labour and if post-partum haemorrhage occurs [18]. 
Pethidine: Pethidine is an opioid agonist. When using Pethidine as pain killers before and 
during labour, it is observed impaired search and sucking behaviour, delayed lactation, 
reduced level of alertness and respiratory depression in new-born babies [18]. Pethidine 
passes easily across the placenta by passive diffusion, and the metabolite Norpethidine has a 
half-life of 60 hours in the new-born baby [20].  
Dihydralazine (Nepresol): The mechanism of action is almost the same as for Hydralazine. It 
causes dilatation of arterioles, reduces peripheral resistance and increases cardiac output. It 
also increases renal blood flow. It is partially converted to Hydralazine [18]. 
Captopril: Captopril is an ACE- inhibitor which decreases conversion of angiotensin I to 
angiotensin II and the breakdown of bradykinin. The effects are mainly caused by reduction 
of angiotensin II which leads to increase of renin that further increase angiotensin I. 
Reduction of angiotensin II decreases sympathetic activity which leads to a dilatation of 
arteries and veins. The peripheral vascular resistance decreases. It is also a release of 
aldosterone from the adrenal glands. That causes increased excretion of sodium and water 
and decreased excretion of potassium and magnesium. Renal perfusion increases [18]. 
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Betamethasone: It is a glucocorticoid that is given to the mother if expected threatening 
preterm birth > 23 weeks and < 34 weeks of gestation, to increase the lung maturation of 
the foetus. It is ideal that it is given 24 hours before delivery, but should be given even 
though the birth is expected earlier [18]. 
Surfactant: Curosorf is a naturally surfactant from pork. There are also other unregistrated 
lung surfactant as Bovint Beraktant (Survanta) and synthetic surfactant (Exosurf). It is used in 
premature children < 34 weeks of gestation for lung maturation [18]. 
Aminophylline: The substance in aminophylline is theophylline ethylen diamin [21]. 
Aminophylline can be used to reduce apnea and stimulate breathing in preterm infants [22]. 
2.3.7 Guidelines 
At Haydom Lutheran Hospital there were guidelines on management of pre-eclampsia and 
eclampsia. Short version is below: 
Management of mild pre-eclampsia: 
 Full assessment which includes the following: daily measurement of blood pressure 
(BP) x 2, urine to quantify protein and check of reflexes. They take cross-match and 
check urea, creatinine, bilirubin, AST and ALT. If BP > 150/>100 mmHg, they give 
maintenance anti-hypertensive medication. If BP is >160/>110 mmHg they give 
emergency anti-hypertensive medication.  
 Ultrasound to assess foetal growth and amniotic fluid. 
 If proteinuria is stable at 1+, BP well controlled and <160/<110 mmHg, normal blood 
tests and no symptoms, the patient can be managed as an outpatient with follow-up 
of BP, urine and foetal condition two times per week. If protein rises to 2+ or rise in 
BP, the patient is readmit to the hospital. 
 Induction of labour above week 37 of gestation [23]. 
Management of severe pre-eclampsia: 
 Admission. If diastolic BP > 110 mmHg, emergency anti-hypertensive medication is 
given. 
 Consider starting infusion of magnesium sulphate if birth is planned within 24 hours. 
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 Give Betamethasone (6 mg intra muscular (i.m) every 12 hours for 48 hours – total 24 
mg)) if 26-36 weeks of gestation. 
 Check Haemoglobin (Hb), cross-match, liver function tests, urea, creatinine, clotting 
status. 
 Every hour – check BP, pulse rate (PR), respiratory rate (RR), urine output, reflexes, 
auscultation of lungs (for pulmonary oedema). 
 Limit maintenance fluid to 80 ml/hour. If severe oedema/shortness of breath/unwell, 
then catheterize, measure urine output hourly, and start strict fluid balance chart. 
 Discuss delivery. Control BP, then deliver baby within 24 hours if: 
- > 34 weeks completed weeks of gestation 
- Severe refractory hypertension (BP > 160/>110 mmHg despite treatment) 
- Rapidly worsening symptoms/signs 
- Worsening blood tests 
 If no immediate delivery, arrange ultrasound to assess growth and amniotic fluid 
every 2 weeks [23]. 
Management of eclampsia:  
 Call for help, protect from injuries, standard check ABCD (Airways, Breathing, 
Circulation, Disability). 
 Give Magnesium Sulphate. 
 If diastolic BP > 110 mmHg, emergency anti-hypertensive medication is given. 
 Catheterize measure urine output hourly, start strict fluid balance chart. 
 Check Hb, Glasgow Coma Scale (GCS), blood slide, liver function tests, clotting status. 
 Every hour – check BP, PR, RR, urine output, reflexes, and auscultation of lungs. 
 Monitor for signs of magnesium toxicity (low respiratory rate, loss of reflexes, and 
urine < 30 ml per hour). Give calcium gluconate 10 ml 10 % if signs of toxicity. 
 Deliver baby within 12 hours (when patient is stable) [23]. 
Post –natal for all these patients: The patient can be discharged if BP is controlled 
<150/<100-80 mmHg, and arrangement of weekly follow-up of hypertension should be 
scheduled. Review 6-8 weeks after birth [23]. 
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Guidelines of medical treatment at Haydom Lutheran Hospital, Tanzania:  
Methyldopa (Aldomet), Nifedipine (Adalat) and Hydralazine are the standard drugs which 
are used for moderate hypertension (BP > 150/>100 mmHg and <160/<110 mmHg). For 
Methyldopa it is normal to start with 250 mg per os (p.o), with maximum daily dose of 1 g. 
For Nifedipine one can start with 10 mg p.o, with maximum daily dose of 30 mg. For 
Hydralazine starting dose is 25 mg p.o, and you can titrate with the same dose times four. 
Methyldopa should be changed to a more effective alternative within 2 days after delivery 
[23]. 
Hydralazine intra venous (i.v) and intra muscular (i.m), and Nifedipine sublingual (under the 
tongue) are the standard drugs which are used for severe hypertension (BP >160/>110 
mmHg). Hydralazine is given 5 mg i.v (over 3-4 minutes) and repeated every 30 minutes if 
diastolic BP > 110 mmHg (maximum total of 20 mg). Hydralazine can also be given 12, 5 mg 
i.m, and be repeated every 2 hours if diastolic BP > 100 mmHg. If the diastolic pressure does 
not decrease after 30 minutes, Nifedipine is given. If Hydralazine is not available or BP is not 
responding, Nifedipine 5 mg sublingual is given and repeated after 10 minutes if diastolic BP 
> 110 mmHg, then 10 mg every 4 hours [23]. 
There were national guidelines for management of pre-eclampsia and eclampsia in Norway 
and a short version is below: 
Management of both mild and severe pre-eclampsia:  
 Measure blood pressure (BP). How often depends on the clinical assessment of the 
pregnant woman. 
 With proteinuria: check urine dip-stick, quantify 24 hour urine, and total 
protein/creatinine ratio. 
 Blood samples: Hb, platelets, AST, ALT, LD, uric acid and creatinine. With severe pre-
eclampsia and HELLP-syndrome also measure albumin, INR, cephotest, fibrinogen, D-
dimer, anti-thrombin and haptoglobin. 
 CTG, ultrasound and Doppler (a. umbilicalis/a. cerebri media). 
 Corticosteroid is given to the mother (in 23/24-34 week of gestation) for lung 
maturation of the foetus, which increases survival for the foetus. 
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 Cervical assessment and clinical options for birth induction. 
 The condition is closely monitored daily, and it can be appropriate to start treatment 
for high BP, treatment with i.v fluid and seizure prophylaxis. Since development of 
pulmonary oedema can occur even after small amounts of fluid i.v, this has to be 
monitored [24]. 
Findings and symptoms in mothers that indicate urgent delivery includes uncontrolled BP 
with severe headache and visual disturbances, rapidly increasing and significant proteinuria 
and/or rise in creatinine, eclampsia, thrombocytopenia with rapid decline, severe liver 
affection and pulmonary oedema [24]. 
Findings and symptoms in foetus that indicate urgent delivery includes pathologic CTG, small 
amount of amniotic fluid, severe intrauterine growth retardation, pathologic Doppler and a 
missing or reduced flow in the diastole in measurement of the a.umbilicalis [24]. 
Post natal: If the woman still has hypertension when she is discharged, she needs to be 
followed up. If she had severe pre-eclampsia, eclampsia or HELLP-syndrome, a further 
assessment should be considered (hypertension, renal function, thrombophilia, anti-
phospholipid syndrome) [24]. 
Management of eclampsia: 
- Call for help. Airway control and prevent any injury. 
- Treatment: Diazepam, 10-20 mg, given i.v or rectally will often stop seizures, but 
sometimes a higher dose is necessary. Seizures can also be primarily treated with 
magnesium sulphate. If the first eclamptic fit is stopped by using diazepam, 
prophylactic treatment with magnesium sulphate should be started to prevent a new 
fit. 
- If magnesium sulphate is given, toxicity may occur, so the patient has to be 
monitored the first 2 hours after treatment. If patellar reflex ceases, respiratory rate 
is lower than 10/min and/or urine output is below 25 ml/hour, the infusion of 
magnesium sulphate should be stopped. Antidote can be considered, which is 
Calcium Gluconate.  
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- The patient has to be stabilized before delivery. Often caesarean section is indicated 
if vaginal delivery cannot be expected shortly. 
- The patient is sent to Intensive Care Unit (ICU) after an eclamptic fit to be treated 
and monitored [25].  
National guidelines of medical treatment in Norway: 
With blood pressure > 160/110 mmHg it is indication for medical treatment. The most 
common drugs used to treat pre-eclampsia in Norway are Labetalol (Trandate) and 
Nifedipine (Adalat). One can start with Labetalol (Trandate) 200 mg p.o as a starting dose. It 
should have an effect after 30 minutes. It can be repeated after a few hours. If oral therapy 
cannot be tolerated due to for example nausea, vomiting or rapidly rise in blood pressure, it 
can be given i.v and that should have an effect after 5-10 minutes. It is usual to start with 20 
mg, and if that does not have any effect, one can increase to 40-50 mg i.v. Maximum dose is 
220 mg. Nifedipine is given orally 10 mg x 2, and maximum per day is 40 mg x 2. Nifedipine 
and/or Labetalol are often given in combination with Methyldopa (Aldomet). Dihydralazine 
was previously the leading i.v drug, but is withdrawn from the market in Norway. Seizure 
prophylaxis should be considered in rapid onset of severe pre-eclampsia, and it is 
Magnesium Sulphate that should be given [24]. 
2.4 Limitation of the thesis 
There exists a lot of literature about pre-eclampsia, but I limited the thesis with choosing 
four specific points I wanted to look at; how they follow-up pre-eclamptic women, the 
management and treatment, and the outcome for the mother and the foetus/neonate. The 
subject was chosen due to great interest in gynaecology/obstetrics and Africa, and I wanted 
to compare the health facilities in Tanzania with Norway. I chose case-study because I 
wanted to learn more about the process with these patients at hand, and literature study to 







3.1 The work process  
I followed up 6 patients at the University Hospital of Northern Norway, Tromsø, in February-
May 2013 before my travel to Tanzania in July 2013. With this experience and more 
acknowledge about the subject, I travelled to Haydom Lutheran Hospital in Tanzania and 
worked at a birth department. There were only 2 relevant patients at Haydom the one week 
I worked there, and that is the reason why I have more cases from Norway than in Tanzania. 
In Tanzania I also met some challenges especially regarding the language. I had learned some 
Swahili before I went to Tanzania, and could communicate on an easy level. I had some 
colleagues to translate into English, and I also read the patients’ journal which was in English. 
It was a handwritten journal, which sometimes could be hard to understand. I collected 
approval and signature from the women in my 8 cases, and assured them that they would be 
anonymous. I went through the local guidelines of pre-eclampsia at Haydom Lutheran 
Hospital and in Norway I had to find the national guidelines in literature. At Haydom 
Lutheran Hospital in Tanzania I asked the staff questions about how they follow up pre- 
eclamptic patients, the management, and what they thought were the challenges about this 
group of patients thinking about the outcome for the mother and foetus/neonate. I also 
spent some time at the New-born Intensive at Haydom Lutheran Hospital, where I followed 
up a preterm infant born in 34 weeks of gestation by an eclamptic mother. 
At the University Hospital of Northern Norway, Tromsø, I searched through the birth 
protocol from 20.08.12- 20.08.13 to look at the incidence of pre-eclampsia, percent of 
primigravidae, percent of preterm deliveries and the choice of delivery. In Tanzania I did not 
have the opportunity to do so due to lack of research approval. The process of getting the 
approval was very complicated and I found out that it was not necessary to get it for this 
small thesis. That is why I had to find the incidence of pre-eclampsia in Tanzania in literature. 
Literature also describes the rate of primigravidae, preterm births and the rate of caesarean 
section in this group of patients. 
Regarding literature I mostly searched in Pubmed, Cochrane and The Norwegian Medical 
Association. My search criteria were “pre-eclampsia”, “pre-eclampsia in Tanzania”, “pre-
eclampsia in Norway”, “perinatal mortality”, “neonatal mortality”, “maternal mortality”, 
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“management pre-eclampsia”, “medications pre-eclampsia” and “prematurity pre-
eclampsia. I searched and read through a lot of articles, and chose the ones that highlighted 
my title. During fall 2013 I read through the chosen articles about the subject pre-eclampsia 
and I also started writing the thesis in this period. The work with writing the thesis continued 
from January to May 2014. 
3.2 The methods validity and reliability 
I followed up a total of 8 patients in Norway and Tanzania with interviews and registration of 
medical information. It is not enough patients to draw any conclusions, but the cases 
highlights different aspects of the disease described in literature.  Since I have been in these 
two different institutions working, gaining experience, seeing similarities and differences, I 
have made my own reflections regarding the subject at hand, and I tried to find the same 
results in literature. The few cases in this study cannot be used for any statistic assessment.  
3.3 Available literature and quality of literature 
In my study of the birth protocol at the University Hospital of Northern Norway, Tromsø, I 
found an incidence of pre-eclampsia to be 2, 8 %. This is not a very reliable source since it 
was not stated in the birth control that my case number 3 had pre-eclampsia even though it 
was present. That is why I cannot say that the incidence really was 2, 8 %. In discussion with 
mid-wives at the University Hospital of Northern Norway, Tromsø, it reflects that the 
incidence might be a bit higher. The rate of primigravidae, preterm birth and the rate of 
caesarean section are more reliable, and can be considered as a true fact since it is more 
likely that this is written down in the birth protocol.  
The literature I found is mostly evidence based literature which is reliable. I tried to find 
literature where I could draw lines to my cases, and literature which could answer my title. 
4.0 Results 
Results of my study are based on cases from Haydom Lutheran Hospital in Tanzania and the 
University Hospital of Northern Norway in Tromsø. 
They took a lot more blood samples of the women in Norway than in Tanzania, and they 
measured more frequently, but they did not measure glucose in Norway as they do in 
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Tanzania. To compare with Tanzania I write down the same blood samples that were taken 
in Tanzania, and comment on other blood samples outside the reference area taken in 
Norway. 
Reference areas for the different blood samples in women are: AST: 15-35 U/L, ALT: 10-45 
U/L, Creatinine: 45-90 micromole/L, Urea: 155-350 micromole/L (in women age 18-49), Total 
bilirubin: 5-25 micromole/L, Hb: 11,7-15,3 g/dL (in women age > 12 years), Glucose: 4,0-6,0 
mmol/L [26].  
4.1 Case presentation 
Case 1: The University Hospital of Northern Norway, Tromsø: 
Para 0, gravida 1 (primigravidae). Week of gestation: 35+2. A woman who developed HELLP-
syndrome. The baby was delivered by emergency caesarean section. It was a girl with a birth 
weight of 1670 grams. 
History: For two days she had difficulties breathing, pain in the epigastric area and shoulder 
blades, and she went to the doctor. Her blood pressure was measured to be 200/105 mmHg. 
Platelets were 84 x 10^9/L and she had 3+ protein in the urine. She started developing a 
severe headache. She was in a bad condition and she was transported to the University 
Hospital of Northern Norway, Tromsø, and had an emergency caesarean section with spinal 
anaesthesia.  
The day after the delivery the platelets were 35 x 10^9/L, and two days after the platelets 
were 55 x 10^9/L. She got a platelet concentrate transfusion. Her blood pressure was still 
high. It was taken a serial measurement of the blood pressure which was: 141-163/102-109 
mmHg and she received Labetalol (Trandate) i.v. The day after the platelets increased to 79 x 
10^9/L and the blood pressure had decreased to 147/79 mmHg.  
The neonate was premature and was transferred to New-born Intensive. Since she was 
above week 34 of gestation, mother did not get any Betamethasone (steroids) and the 





Table 1: Lab results of the woman in case 1 with HELLP-syndrome at the University Hospital 
of Northern Norway, Tromsø. 
This woman also had decreased platelets, calcium, albumin, total protein and haptoglobin. 
She had increased fibrinogen and anti-thrombin III. 
Case 2: The University Hospital of Northern Norway, Tromsø:  
Para 1, gravida 2. Week of gestation: 37+3. A woman who developed severe pre-eclampsia. 
She had an induction of labour and a vaginal delivery. It was a boy with a birth weight of 
2590 grams. 
History: She went to the doctor for a pregnancy control in week 37 of gestation, and was 
sent to the University Hospital of Northern Norway, Tromsø. Before the control she had 
been feeling sick and her hands were swollen. At the time of the control she had high blood 
pressure (diastolic blood pressure > 118 mmHg), and she had developed oedema in her legs. 
After admission she also developed a headache. She collected urine, and they measured her 
blood pressure every fifth minute which was 148-157/87-102 mmHg. They also took blood 
samples. On the second day after admission they started with induction. Her blood pressure 
at that time was 161/94 mmHg and she had 4 + protein in the urine. The induction took 
some time, and the baby was delivered two days after. Her blood pressure after delivery was 
126/82 mmHg, and the mother was doing fine.  
The first day after delivery they measured the blood glucose of the infant which was 1, 9 
mmol/L. They supplemented him with some extra milk, and the blood glucose increased to 
3, 1 mmol/L. Other than that the baby was healthy. 
 
 
Blood sample Highest level Lowest level 
AST 113 ↑ 46 ↑ 
ALT 118 ↑ 46 ↑ 
Creatinine 91 ↑ 86 
Urea 446 ↑ 401 ↑ 
Total bilirubin 17 6 




Blood sample Highest level Lowest level 
ALT 14 7 ↓ 
Urea 557 ↑ 474 ↑ 
Hb 14,9 (on admission) 13,7 (post-delivery) 
Table 2: Lab results of the woman in case 2 with severe pre-eclampsia at the University 
Hospital of Northern Norway, Tromsø. 
AST, total bilirubin, glucose and creatinine was not measured. 
Case 3: The University Hospital of Northern Norway, Tromsø: 
Para 1, gravida 2. Week of gestation: 34 + 2. A woman who developed mild pre-eclampsia. 
She tried vaginal delivery, but ended up with an emergency caesarean section due to birth 
asphyxia. It was a boy with a birth weight of 1571 grams. 
History: She went for a check to the doctor in week 30 of gestation. Her blood pressure at 
that time was 138/95 mmHg. Another control in week 32 of gestation she had developed 1+ 
protein in the urine and her blood pressure was 166/95 mmHg. She also had oedema in her 
legs. She was transferred to the University Hospital of Northern Norway, Tromsø, to do an 
ultrasound. The ultrasound showed growth retardation of the foetus. She now had 2+ 
protein in the urine, a rising blood pressure, and she was admitted. The management were 
daily serial measurement of the blood pressure, CTG, collection of urine and blood samples 
were taken. They took an ultrasound every third day to watch the foetus’ weight. Even 
though she was admitted she was allowed to leave the hospital every now and then. They 
waited with an induction of labour until the foetus was above week 34 of gestation. When 
she was 34 weeks, they took a stress test (a drip of 10 IE Syntocinon) to start some 
contractions and see how the foetus responded to that. Then they tried an induction of 
labour. She was given two 0, 2 mg Misoprostol (Cytotec), and after the second one she 
started to get powerful contractions. They put on a CTG and saw decelerations to 80 beats 
per minute (bpm) at every contraction, and they had to do an emergency caesarean section 
with spinal and general anaesthesia. The mother was recovering well after the caesarean 
section, but her blood pressure was still a bit high the first couple of days (145-160/95-100 
mmHg), and then it decreased (135-140/80-90 mmHg). 
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The blood glucose of the infant was low, and he was given glucose i.v. He also got a probe. 
He was transferred to New-born Intensive and put in an incubator. He was given Surfactant 
100 mg/kg/dose, and he was breathing on his own.  
Blood sample Highest level Lowest level 
ALT 25 16 
Creatinine 93 ↑  
Urea 483 ↑ 382 ↑ 
Hb 13,6 12 
Table 3: Lab results of the woman in case 3 with mild pre-eclampsia at the University 
Hospital of Northern Norway, Tromsø. 
AST, total bilirubin and glucose was not measured. 
Case 4: The University Hospital of Northern Norway, Tromsø: 
Para 0, gravida 1 (primigravidae). Week of gestation > 38. A woman who developed severe 
pre-eclampsia. They tried induction of labour, but ended up with an emergency caesarean 
section. It was a boy with a birth weight of 2840 grams 
History: At first she had a normal blood pressure, but 3+ protein in the urine.  Platelets were 
128 x 10^9/L. Then she developed a headache and pain over the right side of the lower 
abdomen. Blood pressure at that time was 153/86 mmHg. She started to collect urine. The 
day after the blood pressure was 155/95 mmHg, and she had also developed oedema in her 
legs. The blood pressure was increasing, to 180/110 mmHg. They gave her 10 mg Nifedipine 
(Adalat) p.o, and the blood pressure stabilized. She now experienced severe headache and 
some radiation to her eyes. The blood pressure increased again, now to 173/103 mmHg. She 
again received 10 mg Nifedipine (Adalat) p.o, and the pressure was normalized. At that time 
they had tried induction of labour where she received five 0, 2 mg Misoprostol (Cytotec). 
Nothing happened, and they had to perform an emergency caesarean section. 
Two days after delivery she was feeling sick, some seconds she lost her consciousness, 
slurred speech, flashing lights and headache. She was advised to lie flat in the bed, and she 
took 100 mg Labetalol (Trandate) p.o. Her blood pressure again was normalized. Two days 
after that episode she had a new episode with dizziness, flashing lights, headache and pain in 
the abdomen. Blood pressure at that time was 177/104 mmHg and she received 10 mg 
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Nifedipine (Adalat) p.o, with effect. After a few days she got a fever, and CRP and leukocytes 
were increased. Her blood pressure was 157/92 mmHg. The doctors thought about 
endometritis, and she got treatment for that. She also got antibiotics i.v in case of a urine 
tract infection. 
The infant was doing fine after the caesarean section. 
Blood sample Highest level Lowest level 
ALT 11  
Urea 215 195 
Hb 13,4 11,6 
Table 4: Lab results of the woman in case 4 with severe pre-eclampsia at the University 
Hospital of Northern Norway, Tromsø. 
AST, total bilirubin, creatinine and glucose was not measured. She had increased CRP and 
leucocytosis. 
Case 5: The University Hospital of Northern Norway, Tromsø: 
Para 0, gravida 1 (primigravidae). Week of gestation: 34+3. A woman who developed severe 
pre-eclampsia and eclampsia after delivery. The baby was delivered by an emergency 
caesarean section due to severe pre-eclampsia and that the baby had a breech presentation. 
It was a girl with a birth weight of 1982 grams. 
She went to a control in week 32+2 of gestation where they discovered an increased blood 
pressure, 140/90 mmHg and 1+ protein in the urine. They estimated the foetus’ weight and 
found growth retardation. In week 33 of gestation she went to another control. Now the 
blood pressure was 150/100 mmHg, and still 1+ protein in the urine. In week 34 she 
developed a constant severe headache, flashing lights and now she had 3+ protein in the 
urine. Blood pressure was 190/110 mmHg. She was given 100 mg Labetalol (Trandate) p.o 
with small effect. Platelets were 143 x 10^9/L. She was very swollen in her face and hands as 
well, and they performed a caesarean section. After that she was feeling weird, she could 
see, but not interpret visual stimuli. Then she developed generalized tonic-clonic seizures. 
They were severe and she was intubated and given Diazepam 7, 5 mg i.v. They took a CT-
scan afterwards which showed some changes in the occipital area.  
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The infant was transferred to New-born Intensive. She got a probe, but otherwise she was 
doing fine. 
Blood sample Highest level Lowest level 
AST 129 ↑ 90 ↑ 
ALT 128 ↑ 31 
Creatinine 63  
Urea 467 ↑ 305 
Hb 9,1 ↓ 8,5 ↓ 
Table 5: Lab results of the woman in case 5 with severe pre-eclampsia and eclampsia 
postpartum at the University Hospital of Northern Norway, Tromsø. 
Total bilirubin was not measured. She also had leucocytosis, decreased haematocrit and 
platelets which were normalized and increased magnesium. Since she had eclampsia it was 
also taken a blood gas. 
Case 6: The University Hospital of Northern Norway, Tromsø: 
Para 0, gravida 1 (primigravidae). Week of gestation: 35+5. A woman who developed severe 
pre-eclampsia, eclampsia before delivery and HELLP- syndrome. The baby was delivered by 
an emergency caesarean section because the mother has had seizures. It was a girl with a 
birth weight of 1670 grams. 
History: In week 33+6 she went to a control, and there they found out that the foetus had 
not gained weight the last two weeks. She had symptoms like flashing lights, pain in her 
neck, blunt, black spots in front of her eyes, headache, nausea and vomiting, and she was 
admitted. Blood pressure on admission was 190/119 mmHg. They gave her Hydralazine i.v 
and Nifedipine 5 mg sublingual. She still had a severe headache, flashing lights, nausea and 
vomiting, and then she was given Labetalol (Trandate) 100 mg x 3 p.o since the blood 
pressure did not decrease. AST og ALT were increased, and platelets were 100 x 10^9/L. She 
got a Nepresol infusion (Dihydralazine) and Nifedipine (Adalat) 20 mg p.o. They also did an 
ultrasound which showed little amniotic fluid. 
She developed eclampsia before delivery, and had generalized clonic-tonic seizures. They 
stopped the seizures with Diazepam 7, 5 mg i.v. Initial status after the seizures was: no 
contact, partly airway obstruction and froth around the mouth. She had centred and normal 
pupils. They gave her a bolus dose of Magnesium Sulphate. She also received an infusion of 
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Labetalol (Trandate) because of systolic blood pressure 150-160 mmHg. Respiratory rate was 
10, and she was blunt. She also had low diuresis and she was swollen. They ordered a CT-
scan which showed some oedema changes along water shade zones in the brain. It could be 
an acute hypertensive encephalopathy or maybe embolic infarctions. They also ordered a 
MRI, which showed most likely PRES-changes in the brain. After she had been to the MRI 
without oxygen, she developed problems focusing with her eyes; she could not look to the 
sides, only straight forward. The pupil on the left side was a little bigger, but both pupils 
reacted to light. Another thing that happened when they removed the oxygen was that the 
SaO2 decreased from 97% to 88%.  
After delivery AST and ALT decreased, and platelets were somewhat the same. Her blood 
pressure was still high, and she received antihypertensive medication.  She still had 
problems with focusing and she had noticed a few changes in her personality. She did not 
remember anything from the seizures, and was feeling bad. 
The infant was ill after the delivery. She was cyanotic and blunt. They had to stimulate the 
baby, ventilate with mask and bag and start with heart compressions. The colour improved 
and the baby whined. Heart rate after 2 min > 150 beats per min. Movement of the baby 
after 4 min. She was transferred to New-born Intensive.  
Blood sample Highest level Lowest level 
AST 87 ↑ 44 ↑ 
ALT 140 ↑ 72 ↑ 
Creatinine 75 68 
Urea 691 ↑ 309 
Total bilirubin 3 ↓ 2 ↓ 
Hb 9,4 ↓ 8,7 ↓ 
Table 6: Lab results of the woman in case 6 with severe pre-eclampsia, eclampsia before 
delivery and HELLP-syndrome at the University Hospital of Northern Norway, Tromsø. 
She also had leucocytosis, decreased haematocrit, platelets which were normalized, albumin 
and total protein, and increased LD. It was also taken a blood gas due to eclampsia. 
Case 7: Haydom Lutheran Hospital, Tanzania 
Para 3, gravida 4. Week of gestation: 33+3. A woman who developed eclampsia on her way 
to the hospital. Her condition before that is uncertain. They tried induction of labour, but 
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ended up with an emergency caesarean section. It was a girl with a birth weight of 1500 
grams. 
History: I saw this woman two days post caesarean section. She was transferred to the 
hospital by an ambulance. She had headache, dizziness, oedema in her face, vomiting, and 
six seizures on her way to the hospital. Blood pressure on admission was 180/120 mmHg and 
2+ protein in the urine. They gave her Magnesium Sulphate i.v and Nifedipine 10 mg 
sublingual. The blood pressure only decreased to 163/110 mmHg. Then she was given 
Captopril 12, 5 mg p.o, and the blood pressure decreased to 167/81 mmHg. After a while the 
blood pressure increased again, 136-145/101-110 mmHg. She got Nifedipine 5 mg 
sublingual, and the blood pressure dropped again. She was given Betamethasone 12 mg i.m 
(steroids) because of gestation < 34. 0, 2 mg Misoprostol (Cytotec) for induction of labour 
was given times seven, but with no effect. They gave her Pethidine 50 mg x 2 i.m due to 
pain. It ended up with an emergency caesarean section in spinal anaesthesia because of 
induction failed.  She received antibiotics afterwards, to prevent infection. 
Her blood pressure after delivery was 100-160/70-104 mmHg. Nifedipine 20 mg sublingual 
was given. She still had 2+ protein in the urine. The mother was not feeling good even 
though the blood pressure was decreasing. Her reaction was slow, and she did not seem 
well.  
The infant was transferred to New-born Intensive and there she received Aminophylline due 
to apnoea, and she also received glucose and lactogen 
Blood sample Level 
Glucose 6,2 ↑ 
AST 68 ↑ 
ALT 46 ↑ 
Creatinine 110 ↑ 
Urea 637 ↑ 
Total bilirubin 8 
Hb 12,8 
Table 7: Lab results of the woman in case 7 with eclampsia before delivery at Haydom 




Case 8: Haydom Lutheran Hospital, Tanzania 
Para 1, still born 1, gravida 3. 32 weeks of gestation on admission. A woman with known 
pregnancy induced hypertension, and who suddenly developed proteinuria. Pre-eclampsia? 
Pregnancy induced hypertension and a UTI? 
History: She developed pre-eclampsia in her first pregnancy, which is a risk factor for getting 
pre-eclampsia in next pregnancy [15]. Foetus in her first pregnancy unfortunately died, and 
she was really scared of getting pre-eclampsia again. Her symptoms this time were 
headache, palpitations in her chest, epigastric pain and vomiting. In week 29 of gestation her 
doctor measured a high blood pressure. He gave her Labetalol (Trandate) p.o which she took 
daily. She continued measuring blood pressure every day since she lived near the hospital, 
and that her blood pressure changed all the time.  
On admission to the hospital she had developed proteinuria and small oedema in her legs. 
They did a serial measurement of her blood pressure. One measurement was 170/110 
mmHg, and then she received Nifedipine 10 mg sublingual. The blood pressure decreased to 
160/100 mmHg, and then 100/80 mmHg. Five days after, the doctor put her on Antibiotics in 
case she had a urine tract infection. Urine dip-stick showed: Nitrite negative. Protein and 
leukocytes positive. She was also put on Methyldopa (Aldomet) 125 mg p.o, and the plan 
was to give Nifedipine 5 mg sublingual if blood pressure > 150/>100 mmHg. 
Unfortunately I do not have more information about this woman, since I had to leave 
Haydom Lutheran Hospital before she delivered. This case shows the aspect of differential 
diagnosis. Did she develop pre-eclampsia? Or did she have a pregnancy induced 
hypertension and developed an UTI?  
Blood sample Highest level Lowest level 
AST 37 ↑ 21 
ALT 55 ↑ 25 
Creatinine 90 78 
Urea 450 ↑ 370 ↑ 
Table 8: Lab results of the woman in case 8 with pregnancy induced hypertension and an UTI 




Age Para/gravida Gender Gest. age Weight Delivery Causes 
32 P1/G2 Girl 37+3 2810 C/S Pre-eclampsia 
19 P0/G1 Boy >38 2240 Vaginal Pre-eclampsia 
26 P1/G2 Boy >38 4475 Vaginal Pre-eclampsia 
18 P0/G1 Boy >38 3380 Vaginal  Pre-eclampsia 
39 P2/G3 Boy 27+6 764 C/S Pre-eclampsia 
29 P1/G2 Boy >38 3640 Vaginal Pre-eclampsia  
32 P0/G1 Girl 35+2 1670 C/S HELLP syndrome 
29 P1/G2 Boy 37+3 2590 Vaginal Pre-eclampsia 
27 P1/G2 Boy 34+2 1571 C/S Pre-eclampsia 
20 P0/G1 Girl >38 2031 C/S Eclampsia 
31 P1/G2 Girl <38 4335 C/S Pre-eclampsia 
25 P0/G1 Boy >38 3740 Vaginal Pre-eclampsia 
25 P0/G1 Boy >38 2840 C/S Pre-eclampsia 
31 P2/G3 Girl >38 2845 Vaginal Pre-eclampsia 
44 P2/G3 Boy >38 3910 C/S Pre-eclampsia 
26 P0/G1 Girl 34+3 1982 C/S Eclampsia post C/S 
27 P0/G1 Girl 35+5 1670 C/S Eclampsia 
37 P0/G1 Twins 31+5 1247/1810 C/S Severe pre-eclampsia 
38 P4/G5 Girl 27+4 686 C/S Severe pre-eclampsia 
23 P0/G1 Boy >38 3800 C/S Pre-eclampsia 
24 P0/G1 Girl 30+4 1085 C/S Severe pre-eclampsia 
23 P0/G1 Girl >38 3240 C/S Pre-eclampsia 
20 P0/G1 Girl >38 3420 C/S Severe pre-eclampsia 
20 P0/G1 Boy >38 3460 Vaginal Pre-eclampsia 
32 P0/G1 Girl >38 4200 C/S Severe pre-eclampsia 
37 P1/G2 Girl >38 4110 Vaginal Pre-eclampsia 
27 P0/G1 Girl 36 1892 C/S Pre-eclampsia 
31 P0/G1 Boy >38 4235 C/S Pre-eclampsia 
34  P0/G1 Boy 30+1 1160 C/S Severe pre-eclampsia 
31 P0/G1 Boy >38 2915 C/S Eclampsia 
20 P0/G1 Boy 33+5 1895 C/S Severe pre-eclampsia 
37 P1/G2 Boy 35+4 2070 Vaginal HELLP syndrome 
19 P0/G1 Boy 29+2 1209 C/S Eclampsia 
36 P1/G2 Boy >38 4700 C/S Pre-eclampsia 
26 P0/G1 Boy >38 3920 Vaginal Pre-eclampsia 
29 P0/G1 Boy 33+3 3110 C/S Severe pre-eclampsia 
28 P0/G1 Twins 29 1081/745 C/S Pre-eclampsia 
28 P1/S1/G3 Girl 30 1225 C/S Severe pre-eclampsia 
Table 9: Birth protocol from the University Hospital of Northern Norway, Tromsø, in the 
period 20.08-12 – 20.08.13.  
There were 38 cases of pre-eclampsia (eclampsia and HELLP-syndrome are included since 
pre-eclampsia usually is present at first) among 1342 deliveries, so the incidence of pre-




5.0.1 How they follow-up women with pre-eclampsia in Tanzania and Norway 
There are guidelines on how to follow-up pre-eclamptic women in both Norway and 
Tanzania, but as mentioned earlier Tanzania has greater challenges due to long travel 
distance, that it is expensive to both get there and to stay at the hospital [6], [10]. The 
challenges may also be a result of inadequate information on when to seek help and maybe 
where to seek help and this is worsened by poverty and the costs of health care. Lack of 
access to quality care is a big obstacle to reduce maternal mortality in low-income countries. 
This is due to the location and the distance to the hospital and lack of transport. The last fact 
is that it is a delay in health service provision. Lack of trained personnel and lack of 
equipment and supplies are the main reason for that [10]. In a case-control study done in 
rural northern Tanzania, at Haydom Lutheran hospital, they discovered that some women in 
their study did not dare to go to the hospital or other health facility care without their 
husband’s permission. If their husband is not at home at the time of the delivery, it can lead 
to a severe outcome for both the mother and the foetus/neonate [27].  
The follow-up regimes in Tanzania differ from the Norwegian follow-up protocol simply due 
to poor funding of the health care system, lack of diagnostic tools, great travel distances, 
expensive journeys and expensive treatment, relative to the socio-economical state of the 
country [6], [10]. They have greater challenges regarding sending home a pre-eclamptic 
woman or not. Since it is expensive to stay at the hospital, some women choose to leave the 
hospital even though it is necessary that they stay there. Sometimes it is not possible to 
follow up the woman if she lives far from a hospital or a mother-baby-station. Complications 
both for the mother and the foetus/neonate may occur, and she might give birth at home, 
and in that case Tanzania has more challenges compared to Norway. 
5.0.2 Treatment in Tanzania and Norway 
It was regarding the treatment I found the biggest similarity in these two countries, to my 
surprise since there are socioeconomic differences. They use somewhat the same 
medications and have somewhat the same standards and guidelines on when they are being 
given. The only differences I found in this case was that in an eclamptic fit in Norway, the 
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women are more likely to receive Diazepam to stop the seizures, and in Tanzania they give 
Magnesium Sulphate. Two of my cases from the University Hospital of Northern Norway, 
Tromsø, developed eclampsia, and the seizures were controlled by giving Diazepam. In 
Tanzania is seems like they use more Magnesium Sulphate, which also is according to 
guidelines from WHO [5]. In Norway they also used Magnesium Sulphate to prevent another 
seizure. When the mother had an eclamptic fit, it was taken a blood gas in Norway, but this 
was not done in Tanzania due to lack of equipment.  
In Norway the most common drug was Labetalol (Trandate), and in Tanzania this drug was 
not in their guidelines, but can clearly be used for pregnancy induced hypertension since my 
patient in case 8 from Haydom received Labetalol (Trandate). Nifedipine was often used in 
both of these countries, the only difference was that in Tanzania it was more normal to give 
it sublingual, and in Norway it is more common to give orally. Despite that, a woman in one 
of my cases from Norway received Nifedipine sublingual due to malignant hypertension.  
My experience is that Pethidine is frequently used in developing countries, after working in 
both Tanzania and South-Africa. It is almost never used in Norway anymore due to the fact 
that it gives more sedation than an effect on the pain, and is correlated to a number of 
adverse effects on both the mother and the foetus. The metabolite Norpethidine formed by 
Pethidine might give the new-born baby severe respiration depression and the drug has now 
been dissuaded as birth analgesia in Norway [20]. In Tanzania they did not use epidural 
anaesthesia, and I think that can be a reason for the frequently use of Pethidine. Regional 
anaesthesia like epidural and spinal or a combination of these two gives great pain relief and 
lowers incidence of side effects [20]. 
Dihydralazine (Nepresol) is supposed to be withdrawn from the market according to the 
national guidelines in Norway, but was still used in my case number 6. I did not see this 
medicine in Tanzania. Captopril should not be used in pregnant women due to risk of renal 
dysplasia in the foetus, growth retardation and foetal death [18]. This drug was given to my 
case number 7 at Haydom Lutheran Hospital in Tanzania. She had malignant hypertension, 
but it is uncertain why they chose to give her this drug rather than other drugs which are 
better for the foetus. 
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After working at Haydom Lutheran Hospital in Tanzania, I discovered that every woman that 
needed caesarean section received antibiotics afterwards, to prevent infection. After 
working at the birth department at the University Hospital in Northern Norway in Tromsø for 
3 years, I have not seen this being given as a prophylaxis.  
5.0.3 The pregnancy outcome for the mother in Tanzania and Norway 
About 50 000 maternal deaths occur each year due to eclampsia, which is a severe 
complication of pre-eclampsia, and the majority is in developing countries because of low 
standard of health care and limited resources [28]. Maternal death in Europe is a rare event 
and the maternal mortality ratio (MMR) is a lot higher in developing countries [2]. Pre-
eclampsia and eclampsia globally accounts for 10-15% of all maternal deaths [29].  
Maternal mortality in Tanzania is 117, 2 per 100 000 births and abortions [6]. Tanzania has in 
that case one of the highest maternal mortality rate in sub-Saharan Africa. An increased risk 
of maternal deaths was found in women with higher age. In a case-control study in rural 
northern Tanzania they found the mortality to be higher in the age group 35-49 years 
compared to 15-24 years. The main catchment area of this study was done at Haydom 
Lutheran Hospital, Tanzania. Several other studies have revealed risk factors for maternal 
deaths in Tanzania and elsewhere, and the risk factors discovered were parity, age, 
education of mothers, obstetric factors, lack of health facilities and trained personnel and 
socio-economic factors [27]. Seen that the parity in Tanzania is higher in Norway, that there 
are more trained personnel and better equipment in Norway and better information for the 
pregnant woman about when to seek health care, I mean that the women in Norway will 
have a better outcome compared to Tanzania. 
50 % of all births in Tanzania occur at home [6]. Regarding that Tanzania has even more 
challenges than Norway, and there are higher complications both for the mother and the 
foetus/neonate in Tanzania due to home deliveries. A pre-eclamptic woman needs 
treatment and health care, because it is a potential lethal disease which can be complicated 
by for an example eclampsia. These women need to be in the hospital to get a better 
outcome [30]. Eclampsia could be prevented with early booking for antenatal care services, 
early identification of pre-eclampsia and institution of appropriate therapy. In a study poor 
utilization of antenatal care services has been identified as a contributing factor to a high 
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incidence of eclampsia. Eclampsia is also a potentially lethal disease which can be treated, 
but it is better to try and prevent this from occurring [29].  
The rates and adverse outcomes of women with pre-eclampsia are higher in developing 
countries due to greater challenges in health care [6], [10] Pre-eclampsia alone is the reason 
for 12- 18 % of maternal mortality, and the highest maternal mortality rate due to this 
disease is reported in developing countries. In a study in a tertiary care centre in a 
developing country, they concluded that close and frequent observation of maternal status 
showed reduced risk for the mother [30]. It is essential that these women are followed up 
closely, receive the right treatment and deliver when it is appropriate for both the mother 
and the foetus. It is important that the pre-eclamptic women are present at the hospital 
when they develop eclampsia so it can be treated. The outcome can be severe for the 
mother if she gets seizures at home. The neonate might be premature and/or has low birth 
weight for an example and needs treatment. The woman in case number 7 from Haydom 
Lutheran Hospital in Tanzania got seizures at home, but got to the hospital quite rapid and 
received adequate and good health care, and even though the infant was preterm, she 
survived and was doing fine.  
Seen from table 9, nulliparous women (primigravidae) at the University Hospital of Northern 
Norway, Tromsø, was:  24/38 = 63 %, which correlates well to other findings in literature, 
where it is written that 65-75 % of pre-eclamptic women are primigravidae [9]. As 
mentioned previously null parity is a predisposing factor for developing pre-eclampsia [15]. 
In a case-control study done in rural northern Tanzania, they observed that primigravidae 
and women with parities of higher order were at increased risk of maternal death [27]. Since 
pre-eclampsia most frequently occurs in primigravidae, and that higher maternal age also is 
one of the risk factors for developing pre-eclampsia, some maternal deaths may be indirectly 
caused by pre-eclampsia.  
In case 5 and 6 from the University Hospital of Northern Norway, Tromsø, the women 
developed trouble with vision after they both had generalized tonic-clonic seizures. Visual 
changes are reported in 20 % of women with pre-eclampsia and in 50 % of women that 




5.0.4 The pregnancy outcome for the foetus/neonate in Tanzania and Norway 
When it comes to the outcome for the foetus/neonate, I found huge differences in Tanzania 
compared to Norway. Perinatal mortality reflects maternal health. It also reflects antenatal, 
intra-partum and new- born care, and that is why perinatal mortality is an important health 
indicator. According to a registry based study done at a tertiary care hospital in Northern 
Tanzania in 2000-2010, pre-eclampsia and eclampsia are the leading causes for perinatal 
mortality among the maternal conditions. Perinatal mortality was ranging from 27-124 
deaths/1000 births, depending on the geographical area [11].  
Neonatal mortality has decreased since 1990, but still many countries have no measureable 
progress in that matter. 99 % of the neonatal deaths occur in developing countries. Over the 
half of the deaths occurs because of childbirths at home without a mid- wife or a doctor 
present. Infections, birth asphyxia and preterm birth are the causes of approximately 90 % of 
all neonatal deaths [31]. Since pre-eclampsia can lead to preterm birth, it also means that 
pre-eclampsia can lead to a severe outcome for the foetus/neonate, especially in developing 
countries like Tanzania. In about 20 % of the cases with early onset pre-eclampsia, the 
neonate has a low birth weight [32]. Since New-born Intensive in Tanzania is not well 
equipped, the preterm babies and babies with low birth weight were in greater risk there 
compared to Norway.  
Seen from table 9, the percent of pre-eclamptic patients delivering full-term was: 20/38 = 
52, 5 %, which makes 47, 5 % deliver preterm. Preterm birth is a major cause of mortality 
among new-borns and is estimated to be a reason for about 28 % of neonatal mortality 
worldwide each year. There is a huge difference in survival rates between preterm babies 
born in developing countries compared to those who are born in developed countries.  In 
Africa there is a strong association between preterm birth and perinatal mortality. A registry-
based cohort study done in northern Tanzania showed that among other conditions, pre-
eclampsia was a reason for delivering preterm. This association has also been reported by 
others [33]. This seems to be the case in Norway as well, according to my data from the birth 
protocol. I have previously mentioned several risk factors for developing pre-eclampsia, and 
history of a previous pregnancy complicated by pre-eclampsia is one of them [15]. In the 
same registry-based cohort study they found that pre-eclampsia in a previous pregnancy 
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increased the risk of preterm birth threefold. They also mentioned that recurrent pre-
eclampsia increase the likelihood of delivering preterm, and that is also due to complications 
related to pre-eclampsia and the doctor’s tendency for early intervention such as caesarean 
section [33]. Since there is limited access to neonatal care in Tanzania, there is an increased 
risk for the babies there compared to Norway, where there is high standards and well 
equipped New-born Intensive.  
 
 
Figure 2: Causes of neonatal death globally in the period 2000-2003 [31].   
Prematurity is the leading cause of neonatal death [31]. It is a huge problem and something I 
think medical doctors should think of dealing with pre-eclamptic patients, since pre-
eclampsia may lead to prematurity. 
The 8 cases show that infants of pre-eclamptic women often are premature and/or have low 
birth weight. If the baby is preterm, the mother gets Betamethasone (steroids) before 
delivery, and this is done both in Tanzania and Norway. If indicated and age of gestation is < 
34, the neonate in Norway receives Surfactant after being born. This is an expensive drug, 
and is not given to the preterm infants in Tanzania. Instead they are given Aminophylline if 
they have apnoea. It might be important for the neonates to get a CPAP for improved 
respiration and gas exchange, but they are not equipped with this in Tanzania. They do have 
a respirator, but without the possibility to take a blood gas. Preterm infants and infants with 
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low birth weight often have low blood glucose, which is always measured at New-born 
Intensive in Norway. In Tanzania they do not measure that, but all preterm gets glucose and 
lactogen to prevent low blood glucose (Linde pers com) 
Looking at table 9, the rate of caesarean section in pre-eclamptic women was: 27/38 = 71 %. 
The global rate of caesarean section in pre-eclamptic women is also estimated to be around 
high, and around 70 % of these deliver preterm [1]. The high rate of caesarean section 
among these women is very disturbing. Those two factors preterm and high rate of 
caesarean section can be factors for a poor outcome for the neonates, especially in 
Tanzania. Caesarean section has for example shown a high risk of neonatal transfer to New-
born Intensive [12]. Caesarean sections are of course performed to reduce the risk of 
maternal and foetal complications, and are often necessary. Pre-eclampsia and eclampsia 
are known indications for caesarean section. In a study from Medicines sans Frontiers in sub-
Saharan Africa, they found out that one in seven caesarean sections resulted in early 
neonatal death. They said it could be a reflection of inadequate labour management and a 
late transfer to the hospital [34]. Dr. Linde who I spoke to at Haydom Lutheran Hospital 
mentioned the same problem. Pregnant women in Tanzania often arrive late to the hospital, 
and that is one of the reasons that they are late in doing caesarean section, which can result 
in a poor outcome for both the mother and the foetus, superimposed on that caesarean 
section itself can be a risk-factor [12]. Pre-eclampsia/eclampsia and caesarean section have 
an association with early neonatal mortality and maternal mortality [34]. Women with pre-
eclampsia have a lower tolerance for blood loss and a greater risk of haemorrhage; therefor 
vaginal delivery is the best for the mother, but sometimes the maternal condition is severe 
and it will be important to terminate the pregnancy immediately.  Nevertheless the foetus 
could be in great stress and needs to be delivered to save the life of the foetus as well. Then 
the obstetricians have to think of the best mode of delivery and the best time for delivery for 







Pre-eclampsia is not a rare disease in pregnant women, and occur most frequently in 
primigravidae, and this seems to be the same in Tanzania as for Norway, but the incidence of 
pre-eclampsia is probably slightly higher in Tanzania. Several complications both for the 
mother and the infant can occur due to pre-eclampsia, and that is why it is important and 
necessary to follow-up and treat these women on an adequate level. The problem in 
Tanzania is caused by long way to the hospital, expenses connected with transport and to 
stay at the hospital. Therefore many women choose to give birth at home, as many as 50 %. 
It is difficult to follow-up these patients who do not go to the hospital or cannot afford to 
stay there and they have to be sent home. If the pre-eclamptic woman gets admitted and 
stay in the hospital, she gets adequate healthcare and is followed up frequently. In Norway 
we do not have these kinds of challenges as Tanzania, and therefore it is a lot easier to 
follow-up a pre-eclamptic woman in Norway. 
The management of this disease is quite similar in Norway and Tanzania; they take relevant 
blood samples, collect urine, and use somewhat the same drugs both to treat and prevent 
pre-eclampsia and eclampsia. Both institutions use anti-hypertensive medication, but there 
are some differences in which medicine they prefer to use.  
Pre-eclampsia can lead to prematurity because it is necessary to end the pregnancy due to 
either maternal or foetal factor. The neonates also have risk of low birth weight due to 
intrauterine growth retardation caused by pre-eclampsia. The New-born Intensive at 
Haydom Lutheran hospital in Tanzania was not well equipped, so preterm infants and infants 
with low birth weight were at risk there. The outcome of the infant is better in Norway since 
we have more equipment to help the neonates.  
There is high maternal mortality in Tanzania, and one of the reasons can be because of pre-
eclampsia and complications that can occur like for an example eclampsia and/or HELLP-
syndrome. If the woman develops these kinds of severe diseases, she has to be admitted to 
the hospital, get medical treatment and be monitored frequently to have a certain control of 
the situation. In Norway this usually is not a problem since it is free to stay at the hospital 
and they get good health care. 
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A large percentage of pre-eclamptic mothers end up having a caesarean section, which is a 
risk factor in itself, both for the mother and the foetus. The mother is in risk of great blood 
loss and infection, and the baby can be delivered preterm, which is a risk factor as 
mentioned. In Tanzania they give all women with caesarean section antibiotics prophylactic 
to prevent infection, and this is not done in Norway. 
To reduce the large number of both maternal and perinatal/neonatal deaths in developing 
countries such as Tanzania, I mean one should focus on how to follow up and treat women 
with pre-eclampsia. I think it is possible to greatly reduce the morbidity and mortality 
connected with pre-eclampsia and the following complications. In rural areas with limited 
resources, this is one of the easiest things to look at and to do something with. In Norway I 
found the standard of health care very satisfying, and there are very few maternal and 
perinatal/neonatal deaths in Norway. It is important to have good guidelines, which I think 
both of these countries did have. Both of these institutions give good health care in my 
opinion. The main difference is the socioeconomic standard, which gives Tanzania a lot more 
challenges dealing with pre-eclamptic patients. I think that if it is possible to get the 
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